LOGIN
Oral edoxaban vs. subcutaneous enoxaprain for VTE prophylaxis after TKA
February 2015
Oral edoxaban vs. subcutaneous enoxaprain for VTE prophylaxis after TKA
Study Type:Therapy
OE Level Evidence:1
Journal Level of Evidence:N/A
Safety and Efficacy of Edoxaban, an Oral Factor Xa Inhibitor, Versus Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty: The STARS E-3 Trial
Thromb Res. 2014 Dec;134(6):1198-204Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Synopsis
716 Japanese and Taiwanese patients undergoing total knee arthroplasty were randomized to either oral edoxaban 30mg or subcutaneous enoxaparin 2000IU for 11-14 days after surgery. The purpose of this study was to compare efficacy and safety of edoxaban to that of enoxaparin. Venous thromboembolic events and bleeding outcomes were assessed for 25-35 days after the last administration of study drug....
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!
Learn about our AI Driven
High Impact Search Feature
Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.
Continue
Join the Conversation
Please Login or Join to leave comments.